The field of plasma medicine has advanced significantly in recent years and provides benefits across numerous applications. While much of this progress stems from innovative research tools, there is still a lack of approved medical instruments suitable for patient care in markets like the United States. Although various argon plasma coagulators are already approved for medical use, their high thermal energy often makes them unsuitable for plasma medicine. This study explores the potential of a commercial helium plasma tool for delivering low-energy, nonthermal discharges to wound sites. Specifically, the J-Plasma device by Apyx Medical utilizes low-temperature helium plasma to provide precise power with minimal thermal spread. Our research investigates how this technology affects nebulized biologic materials, demonstrating a minimal impact on protein chemical structure. We also discuss the ability to deliver biologics while controlling wound surface modification, supported by preliminary in vivo data from a rodent burn model.
